免疫检查点抑制剂联合治疗肝癌的进展

孙涛; 任衍乔; 操焱焱; 郑传胜

doi:10.3969/j.issn.1001-5256.2020.06.043

免疫检查点抑制剂联合治疗肝癌的进展

DOI: 10.3969/j.issn.1001-5256.2020.06.043

华中科技大学同济医学院附属协和医院放射科

基金项目:

国家自然科学基金(81873919)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 1018
- HTML全文浏览量: 55
- PDF下载量: 154
- 被引次数: 0
出版历程
- 出版日期: 2020-06-20

Advances in immune checkpoint inhibitor combined with other treatment methods for hepatocellular carcinoma

Research funding:

摘要

摘要:
免疫检查点抑制剂（ICI）治疗不可切除性肝癌近年来受到国内外研究者的极大关注,取得重大进展,但ICI单药治疗并不能使大多数肝癌患者受益。因此,探讨ICI联合其他治疗方法成为新的研究趋势。归纳了近些年国内外关于不可切除性肝癌ICI联合治疗相关进展,包括了联合分子靶向治疗、PD-1/PD-L1抑制剂联合CTLA-4抑制剂及联合局部治疗。分析表明,对于不可切除性肝癌患者,ICI联合其他治疗方法明显优于ICI单药治疗,但联合何种治疗方式能够使患者获益程度最佳,仍需进一步探索。
- 肝肿瘤 /
- 免疫抑制剂 /
- 药物疗法,联合
Abstract:
In recent years,immune checkpoint inhibitor( ICI) in the treatment of unresectable liver cancer has attracted great attention in China and foreign countries and great progress has been achieved,but ICI monotherapy cannot bring benefits to most patients with liver cancer. Therefore,it is a new trend to explore the combination of ICI with other treatment methods. This article summarizes the advances in ICI combination therapy for unresectable liver cancer in China and foreign countries,including ICI combined with molecular targeted therapy,PD-1/PD-L1 inhibitor combined with CTLA-4 inhibitor,and ICI combined with local therapy. The results show that for patients with unresectable liver cancer,ICI combined with other treatment methods has a significantly better effect than ICI monotherapy; however,further studies are needed to explore which treatment method combined with ICI can bring the greatest benefits to patients.
- liver neoplasms /
- immunosuppressive agents /
- drug therapy,combination

HTML全文

参考文献(27)

[1] BRAY F,FERLAY J,SOERJOMATARAM I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.

[2] BOLAND P,WU J. Systemic therapy for hepatocellular carcinoma:Beyond sorafenib[J]. Chin Clin Oncol,2018,7(5):50.

[3] LIN CL,CHIEN RN,LIN SM,et al. An occult hepatitis B-derived hepatoma cell line carrying persistent nuclear viral DNA and permissive for exogenous hepatitis B virus infection[J].PLo S One,2013,8(5):e65456.

[4] KNOLLE PA,THIMME R. Hepatic immune regulation and its involvement in viral hepatitis infection[J]. Gastroenterology,2014,146(5):1193-1207.

[5] IWAI Y,HAMANISHI J,CHAMOTO K,et al. Cancer immunotherapies targeting the PD-1 signaling pathway[J]. J Biomed Sci,2017,24(1):26.

[6] SIA D,JIAO Y,MARTINEZ-QUETGLAS I,et al. Identification of an immune-specific class of hepatocellular carcinoma,based on molecular features[J]. Gastroenterology,2017,153(3):812-826.

[7] LIU Z,LIN Y,ZHANG J,et al. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma[J]. J Exp Clin Cancer Res,2019,38(1):447.

[8] LIANG SC,LATCHMAN YE,BUHLMANN JE,et al. Regulation of PD-1,PD-L1,and PD-L2 expression during normal and autoimmune responses[J]. Eur J Immunol,2003,33(10):2706-2716.

[9] CAO YQ,JIN X,SUI SN,et al. Advances of chimeric antigen receptor T-cell immunotherapy combined with immune checkpoint inhibitors in malignancies therapy[J]. Chin J Clin Oncol,2018,45(9):472-476.(in Chinese)曹雅青，金鑫，隋松男，等．嵌合抗原受体T细胞联合免疫检查点抑制剂治疗恶性肿瘤的研究进展[J]．中国肿瘤临床，2018,45(9):472-476.

[10] CUI YL. Targeted therapy for hepatocellular carcinoma[J].Chin J Dig Surg,2018,17(5):445-451.(in Chinese)崔云龙．肝癌的靶向治疗[J]．中华消化外科杂志，2018,17(5):445-451.

[11] XU W,LIU K,CHEN M,et al. Immunotherapy for hepatocellular carcinoma:Recent advances and future perspectives[J].Ther Adv Med Oncol,2019,11:1758835919862692.

[12] HANAHAN D,WEINBERG RA. Hallmarks of cancer:The next generation[J]. Cell,2011,144(5):646-674.

[13] SWART M,VERBRUGGE I,BELTMAN JB. Combination approaches with immune-checkpoint blockade in cancer therapy[J]. Front Oncol,2016,6:233.

[14] LARKIN J,CHIARION-SILENI V,GONZALEZ R,et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma[J]. N Engl J Med,2015,373(1):23-34.

[15] KELLEY RK,ABOU-ALFA GK,BENDELL JC,et al. PhaseⅠ/Ⅱstudy of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma(HCC):PhaseⅠsafety and efficacy analyses[J]. J Clin Oncol,2017,35(15 Suppl):4073.

[16] YUAN GQ,MO CJ,ZHANG ZC. Clinical effect of TACE combined with radiofrequency ablation in the treatment of primary liver cancer[J]. Clin J Med Offic,2019,47(10):1126-1127.(in Chinese)袁广庆，莫灿均，张志成．肝动脉化疗栓塞联合射频消融治疗原发性肝癌临床疗效观察[J]．临床军医杂志，2019,47(10):1126-1127.

[17] GRETEN TF,SANGRO B. Targets for immunotherapy of liver cancer[J]. J Hepatol,2017.[Online ahead of print]

[18] LEE S,KIM H,JI Y,et al. Evaluation of hepatic toxicity after repeated stereotactic body radiation therapy for recurrent hepatocellular carcinoma using deformable image registration[J].Sci Rep,2018,8(1):16224.

[19] ABUODEH Y,VENKAT P,KIM S. Systematic review of case reports on the abscopal effect[J]. Curr Probl Cancer,2016,40(1):25-37.

[20] LENCIONI R,de BAERE T,SOULEN MC,et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma:A systematic review of efficacy and safety data[J]. Hepatology,2016,64(1):106-116.

[21] de TONI EN. Immune checkpoint inhibitors:Use them early,combined and instead of TACE?[J]. Gut,2019.[Online ahead of print]

[22] EL-KHOUEIRY AB,SANGRO B,YAU T,et al. Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate 040):An open-label,non-comparative,phase 1/2 dose escalation and expansion trial[J]. Lancet,2017,389(10088):2492-2502.

[23] SHI L,CHEN L,WU C,et al. PD-1 blockade boosts radiofrequency ablation-elicited adaptive immune responses against tumor[J]. Clin Cancer Res,2016,22(5):1173-1184.

[24] DUFFY AG,ULAHANNAN SV,MAKOROVA-RUSHER O,et al.Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma[J]. J Hepatol,2017,66(3):545-551.

[25] SANGRO B,GOMEZ-MARTIN C,de la MATA M,et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C[J]. J Hepatol,2013,59(1):81-88.

[26] Correction:Gut roundtable meeting paper:Selected recent advances in hepatocellular carcinoma[J]. Gut,2018,67(3):594.

[27] MARTINS F,SOFIYA L,SYKIOTIS GP,et al. Adverse effects of immune-checkpoint inhibitors:Epidemiology,management and surveillance[J]. Nat Rev Clin Oncol,2019,16(9):563-580.

施引文献

资源附件(0)

访问统计